Search - tctmd.com

Displaying 281 - 300 of 480

Sort: Relevancy | Date

Presentation TCT 2016

Aortic Stenosis + Concomitant Disease III. TAVR in Patients With Atrial Fibrillation - Outcomes, Adjunctive Pharmacology, and Accessory Therapies (Including LAA Closure)

Presenter: A. Pieter Kappetein, Allan Schwartz, Samir R. Kapadia

October 30, 2016

Presentation TCT 2016

Debate #1: Should Low bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? Yes As Long As Full Consent Is Provided, Let the Patient Decide!

Presenter: David R. Holmes Jr., Josep Rodés-Cabau, David Hildick-Smith

October 30, 2016

Presentation TCT 2016

Debate #1: Should Low Bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? No Chronic Anticoagulation Should be Offered First

Presenter: David R. Holmes Jr., Josep Rodés-Cabau, Stefan C. Bertog

October 30, 2016

Presentation TCT 2016

Treatment of Renal Artery Fibromuscalar Dysplasia: Indications, Techniques, and Outcomes

Presenter: Gary M. Ansel, Michael R. Jaff, Mehdi H. Shishehbor

October 30, 2016

Presentation TCT 2016

Renal Artery Fibromuscular Dysplasia: Natural History and Treatment

Presenter: Gary M. Ansel, Michael R. Jaff

October 30, 2016

Presentation TCT 2016

TCT 648: Atrial Fibrillation in Patients Undergoing Transcatheter Aortic Valve Replacement

Presenter: Jean-Claude Laborde, Azfar G. Zaman

October 30, 2016

Presentation TCT 2016

Risk Scores for Stroke Risk and Bleeding in Atrial Fibrillation: Accuracy and Utility in Trials and the Real World

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Christopher B. Granger

October 30, 2016

Presentation TCT 2016

Outcomes and Role of Ablation in the Treatment Approach to Atrial Fibrillation

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Vivek Y. Reddy

October 30, 2016

Presentation TCT 2016

What are Valid Absolute and Relative Contraindications to Warfarin and NOACs?

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Michelle O'Donoghue

October 30, 2016

Presentation TCT 2016

Impact of LAA Exclusion on Neurohormonal Modulation

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Role of LAA in Atrial Arrhythmias: Origin and Maintenance

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Atrial Fibrillation: Scope of the Problem

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Michael D. Ezekowitz

October 30, 2016

Presentation TCT 2016

TAVR in Patients With Atrial Fibrillation

Presenter: Neal S. Kleiman, Patrick T. O'Gara, Fabian Nietlispach

October 30, 2016

Presentation TCT 2016

Atrial Fibrillation Double vs Triple Therapy Considerations and Ongoing Trials

Presenter: Sorin J. Brener, Franz-Josef Neumann, Pascal Vranckx

October 30, 2016

Presentation ESC 2016

Edoxaban vs Enoxaparin-Warfarin in Subjects UndergoingCardioversion of Atrial Fibrillation

Presenter: Andreas Goette

August 30, 2016

Presentation

Outcomes of Patients With Atrial Fibrillation Undergoing PCI

Presenter: NR. Sutton

August 24, 2016

Presentation

Warfarin and Antiplatelet Therapy vs Warfarin Alone for Treating Patients with A-fib Undergoing TAVR

Presenter: Abdul-Jawad Altisent

August 16, 2016

Presentation TVT 2016

Combined TAVR and Left Atrial Appendage Closure in AS Patients With Atrial Fibrillation: Case Selection, Procedural Consideration, and Clinical Outcomes

Presenter: Fabian Nietlispach

June 17, 2016

Presentation TVT 2016

Complexities of Managing AS Patients With Atrial Fibrillation After TAVR

Presenter: Samir R. Kapadia

June 17, 2016

Advertisement

Aortic Stenosis + Concomitant Disease III. TAVR in Patients With Atrial Fibrillation - Outcomes, Adjunctive Pharmacology, and Accessory Therapies (Including LAA Closure)

Debate #1: Should Low bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? Yes As Long As Full Consent Is Provided, Let the Patient Decide!

Debate #1: Should Low Bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? No Chronic Anticoagulation Should be Offered First

Treatment of Renal Artery Fibromuscalar Dysplasia: Indications, Techniques, and Outcomes

Renal Artery Fibromuscular Dysplasia: Natural History and Treatment

TCT 648: Atrial Fibrillation in Patients Undergoing Transcatheter Aortic Valve Replacement

Risk Scores for Stroke Risk and Bleeding in Atrial Fibrillation: Accuracy and Utility in Trials and the Real World

Outcomes and Role of Ablation in the Treatment Approach to Atrial Fibrillation

What are Valid Absolute and Relative Contraindications to Warfarin and NOACs?

Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance

Impact of LAA Exclusion on Neurohormonal Modulation

Role of LAA in Atrial Arrhythmias: Origin and Maintenance

Atrial Fibrillation: Scope of the Problem

TAVR in Patients With Atrial Fibrillation

Atrial Fibrillation Double vs Triple Therapy Considerations and Ongoing Trials

Edoxaban vs Enoxaparin-Warfarin in Subjects UndergoingCardioversion of Atrial Fibrillation

Outcomes of Patients With Atrial Fibrillation Undergoing PCI

Warfarin and Antiplatelet Therapy vs Warfarin Alone for Treating Patients with A-fib Undergoing TAVR

Combined TAVR and Left Atrial Appendage Closure in AS Patients With Atrial Fibrillation: Case Selection, Procedural Consideration, and Clinical Outcomes

Complexities of Managing AS Patients With Atrial Fibrillation After TAVR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content